The effect and safety of single tablet of fixed dose mitiglinide and voglibose when changed from DPP-4 inhibitor

Trial Profile

The effect and safety of single tablet of fixed dose mitiglinide and voglibose when changed from DPP-4 inhibitor

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2015

At a glance

  • Drugs Mitiglinide/voglibose (Primary) ; CD26 antigen inhibitors
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jul 2015 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 07 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top